Cargando…

Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report

INTRODUCTION: Seizures of autoimmune etiology may occur independent of or predate syndromes of encephalitis. We report a child with “pure” autoimmune epilepsy followed up for 7 years to highlight long-term effects of this epilepsy and the importance of early initiation and appropriate escalation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wanigasinghe, Jithangi, Chang, Thashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527639/
https://www.ncbi.nlm.nih.gov/pubmed/34666812
http://dx.doi.org/10.1186/s13256-021-03117-5
_version_ 1784586108976234496
author Wanigasinghe, Jithangi
Chang, Thashi
author_facet Wanigasinghe, Jithangi
Chang, Thashi
author_sort Wanigasinghe, Jithangi
collection PubMed
description INTRODUCTION: Seizures of autoimmune etiology may occur independent of or predate syndromes of encephalitis. We report a child with “pure” autoimmune epilepsy followed up for 7 years to highlight long-term effects of this epilepsy and the importance of early initiation and appropriate escalation of immunosuppression to achieve a good long-term outcome. CASE PRESENTATION: A previously healthy 5-year-old Sri Lankan boy presented with acute, frequent, brief focal seizures of temporal-lobe semiology without clinical and investigatory findings suggestive of central nervous system infection, tumor, structural abnormality, or metabolic causes. His epilepsy showed poor response to increasing doses and combinations of antiseizure medications. Further investigations detected N-methyl-d-aspartate receptor antibodies in serum, but not cerebrospinal fluid. Treatment with intravenous methyl prednisolone and maintenance on mycophenolate resulted in a rapid reduction, with seizure freedom achieved within 5–6 weeks. He relapsed when immunotherapy and anti seizure medications were reduced after seizure freedom for 24 months. This, and subsequent relapses, showed poor response to modification of anti-seizure medications, but treatment with immunotherapy (methyl prednisolone and rituximab) achieved complete seizure freedom. At 7-years of follow-up, he remains free of seizure for over 3 years, and has average academic performance and satisfactory quality of life. CONCLUSIONS: Autoimmune epilepsy is a recognized independent entity. Diagnostic criteria have been suggested for its early recognition and confirmation of diagnosis. Early diagnosis and initiation of immunosuppression, with prompt escalation of treatment when necessary, remains key to good patient outcome.
format Online
Article
Text
id pubmed-8527639
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85276392021-10-25 Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report Wanigasinghe, Jithangi Chang, Thashi J Med Case Rep Case Report INTRODUCTION: Seizures of autoimmune etiology may occur independent of or predate syndromes of encephalitis. We report a child with “pure” autoimmune epilepsy followed up for 7 years to highlight long-term effects of this epilepsy and the importance of early initiation and appropriate escalation of immunosuppression to achieve a good long-term outcome. CASE PRESENTATION: A previously healthy 5-year-old Sri Lankan boy presented with acute, frequent, brief focal seizures of temporal-lobe semiology without clinical and investigatory findings suggestive of central nervous system infection, tumor, structural abnormality, or metabolic causes. His epilepsy showed poor response to increasing doses and combinations of antiseizure medications. Further investigations detected N-methyl-d-aspartate receptor antibodies in serum, but not cerebrospinal fluid. Treatment with intravenous methyl prednisolone and maintenance on mycophenolate resulted in a rapid reduction, with seizure freedom achieved within 5–6 weeks. He relapsed when immunotherapy and anti seizure medications were reduced after seizure freedom for 24 months. This, and subsequent relapses, showed poor response to modification of anti-seizure medications, but treatment with immunotherapy (methyl prednisolone and rituximab) achieved complete seizure freedom. At 7-years of follow-up, he remains free of seizure for over 3 years, and has average academic performance and satisfactory quality of life. CONCLUSIONS: Autoimmune epilepsy is a recognized independent entity. Diagnostic criteria have been suggested for its early recognition and confirmation of diagnosis. Early diagnosis and initiation of immunosuppression, with prompt escalation of treatment when necessary, remains key to good patient outcome. BioMed Central 2021-10-20 /pmc/articles/PMC8527639/ /pubmed/34666812 http://dx.doi.org/10.1186/s13256-021-03117-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Wanigasinghe, Jithangi
Chang, Thashi
Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report
title Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report
title_full Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report
title_fullStr Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report
title_full_unstemmed Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report
title_short Autoimmune epilepsy due to N-methyl-d-aspartate receptor antibodies in a child: a case report
title_sort autoimmune epilepsy due to n-methyl-d-aspartate receptor antibodies in a child: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527639/
https://www.ncbi.nlm.nih.gov/pubmed/34666812
http://dx.doi.org/10.1186/s13256-021-03117-5
work_keys_str_mv AT wanigasinghejithangi autoimmuneepilepsyduetonmethyldaspartatereceptorantibodiesinachildacasereport
AT changthashi autoimmuneepilepsyduetonmethyldaspartatereceptorantibodiesinachildacasereport